Fed. Circ. Won't Rethink Standing In Myriad Gene Patent Case

Law360, New York (June 14, 2012, 9:27 PM EDT) -- The Federal Circuit on Monday declined to reconsider the standing of the sole plaintiff in a suit challenging the validity of Myriad Genetics Inc.'s breast cancer gene patents, rejecting Myriad's argument that the plaintiff lost standing when he changed jobs, rendering the case moot.

Myriad asked the court in May to dismiss the case because it involves "only abstract, philosophical questions" after the sole plaintiff, Harry Ostrer, left his position at New York University Medical Center for a new job at Montefiore Medical Center.

Ostrer's standing...
To view the full article, register now.